This invention relates to 4 {[4 ({[4 (2 2 2 trifluoroethoxy) 1 2 benzisoxazol 3 yl] oxy}methyl)piperidin 1 yl]methyl}tetrahydro 2H pyran 4 carboxylic acid for use in therapeutic treatment of the human body. In particular it relates to the compound having selective 5 HT4 receptor agonism which is useful for treating gastroparesis or preventing or delaying the onset or the progression of gastroparesis.